Drug Safety

, Volume 25, Issue 5, pp 373–378

Interaction Between Aspirin and ACE Inhibitors

Resolving Discrepancies Using a Meta-Analysis
  • Bahi Takkouche
  • Mahyar Etminan
  • Francisco Caamaño
  • Paula A. Rochon
Original Research Article


Background: Recently, studies have attempted to explore the interaction between ACE inhibitors and aspirin (acetylsalicylic acid) when both drugs are used concomitantly to reduce mortality in patients with coronary artery disease. Results have been conflicting due, in part, to sub-optimal methods used to explore this interaction.

Methods: We reviewed systematically all studies on mortality in patients treated with ACE inhibitors and aspirin and conducted a meta-analysis in order to explore the interaction between both drugs and resolve discrepancies. To be included, each study had to provide data on mortality of patients who received both drugs, either drug and no drug. These data were necessary to calculate the synergy index (S) and its 95% confidence interval (CI) that we used to quantify the effect due to interaction between ACE inhibitors and aspirin. After testing for heterogeneity of effects, we pooled the S values from the individual studies into one summary measure.

Subsequently, we compared our results with those obtained through the most common but incorrect method of evaluating interaction. This method uses significance testing of the relative risk of mortality when a ‘product term’ between ACE inhibitors and aspirin is entered in a logistic regression model.

Results: Eight studies met the inclusion criteria. The pooled synergy index S indicates slight but precise antagonism between ACE inhibitors and aspirin (S = 0.91; 95% CI 0.80 to 1.03). In contrast, the pooled ‘product term’ is not significant and would have lead to the conclusion of absence of interaction (p = 0.15).

Conclusion: There seems to be an antagonistic interaction between ACE inhibitors and aspirin. Former discrepancies were due to inadequate assessment of interaction. Results from the Studies on Left Ventricular Dysfunction (SOLVD) and Heart Outcome Prevention Evaluation (HOPE) trials that assessed the effect of combined administration of ACE inhibitors and aspirin were not included in this meta-analysis because those trials did not provide enough data to compute the S statistic. It is possible that results from on-going trials such as Women’s Atovarstatin Trial on Cholesterol (WATCH) will shed more light on ACE inhibitor and aspirin interaction in the future.


  1. 1.
    The SOLVD investigators. The effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991; 325: 293–302Google Scholar
  2. 2.
    The Heart Outcome Prevention Evaluation Study Investigators. Effects of angiotensin converting inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000; 342: 145–53Google Scholar
  3. 3.
    Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999; 100: 1016–30PubMedCrossRefGoogle Scholar
  4. 4.
    Peterson JG, Topol EJ, Sapp SK, et al. Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease. Am J Med 2000; 109: 371–7PubMedCrossRefGoogle Scholar
  5. 5.
    Al-Khadra AS, Salem DN, Rand WM, et al. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol 1998; 31: 419–25PubMedCrossRefGoogle Scholar
  6. 6.
    Krumholz HM, Chen YT, Wang Y, et al. Aspirin and angiotensin-converting enzyme inhibitors among elderly survivors of hospitalization for an acute myocardial infarction. Arch Intern Med 2001; 16: 538–44CrossRefGoogle Scholar
  7. 7.
    Hallqvist J, Ahlbom A, Diderichsen F, et al. How to evaluate interaction between causes: a review of practices in cardiovascular epidemiology. J Intern Med 1996; 239: 377–82PubMedCrossRefGoogle Scholar
  8. 8.
    Greenland S, Rothman KJ. Concepts of interaction. In: Greenland S, Rothman KJ, editors. Modern epidemiology. 2nd ed. Philadephia: Lippincott-Raven; 1998: 329–42Google Scholar
  9. 9.
    Etminan M, Takkouche B. Interaction between Ace-Is and aspirin [letter]. Arch Intern Med 2001; 161: 2048PubMedCrossRefGoogle Scholar
  10. 10.
    Mahé I, Meune C, Diemer M, et al. Interaction between aspirin and ACE inhibitors in patients with heart failure. Drug Saf 2001; 24: 167–82PubMedCrossRefGoogle Scholar
  11. 11.
    Stys T, Lawson WE, Smaldone GC, et al. Does aspirin attenuate the beneficial effects of angiotensin-converting enzyme inhibition in heart failure? Arch Intern Med 2000; 160: 1409–13PubMedCrossRefGoogle Scholar
  12. 12.
    Rothman KJ. The estimation of synergy or antagonism. Am J Epidemiol 1976; 10: 506–10Google Scholar
  13. 13.
    Takkouche B, Cadarso-Suarez C, Spiegelman D. Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis. Am J Epidemiol 1999; 150: 206–15PubMedCrossRefGoogle Scholar
  14. 14.
    ISIS-4 Fourth International Study of Infarct Survival Collaborative Group — ISIS-4: a randomised factorial trial assessing early oral captopril mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669–85Google Scholar
  15. 15.
    Swedberg K, Held P, Kjekshus J, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the cooperative new scandinavian enalapril survival study II (CONSENSUS II). N Engl J Med 1992; 327: 678–84PubMedCrossRefGoogle Scholar
  16. 16.
    Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glycerine trinitrate singly and together on six week mortality and ventricular function after myocardial infarction. Lancet 1994; 343: 1115–22Google Scholar
  17. 17.
    Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995; 345: 686–7Google Scholar
  18. 18.
    Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995; 332: 80–5PubMedCrossRefGoogle Scholar
  19. 19.
    Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial (SAVE). N Engl J Med 1992; 327: 669–77PubMedCrossRefGoogle Scholar
  20. 20.
    Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670–6PubMedCrossRefGoogle Scholar
  21. 21.
    The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–8Google Scholar
  22. 22.
    Leor J, Reicher-Reiss H, Goldbourt U, et al. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: a cohort study of 11,575 patients with coronary artery disease. J Am Coll Cardiol 1999; 33: 1920–5PubMedCrossRefGoogle Scholar
  23. 23.
    Latini R, Tognoni G, Maggioni AP, et al. Clinical effect of angiotensin converting enzyme inhibitors treatment for acute myocardial infarction are similar in the presence and absence of aspirin. J Am Coll Cardiol 2000; 35: 1801–7PubMedCrossRefGoogle Scholar
  24. 24.
    Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: sub group analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol 1997; 79: 115–9PubMedCrossRefGoogle Scholar
  25. 25.
    Flather MD, Yusuf S, Kober L, et al. Long term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000; 355: 1575–81PubMedCrossRefGoogle Scholar
  26. 26.
    Cleland JG, John J, Dhawan J, et al. What is the optimal medical management of ischaemic heart failure? Br Med Bull 2001; 59: 135–58PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • Bahi Takkouche
    • 1
  • Mahyar Etminan
    • 2
  • Francisco Caamaño
    • 1
  • Paula A. Rochon
    • 3
  1. 1.Department of Preventive MedicineUniversity of Santiago de Compostela, Area de Medicina Preventiva, Facultad de MedicinaSantiago de CompostelaSpain
  2. 2.Kunin-Lunenfeld Applied Research Unit, Department of Clinical Epidemiology, Baycrest Center for Geriatric CareUniversity of TorontoTorontoCanada
  3. 3.Kunin-Lunenfeld Applied Research Unit, Baycrest Centre for Geriatric Care; Departments of Medicine and Public Health Sciences, Faculty of MedicineUniversity of Toronto, Institute for Clinical Evaluative Sciences, Sunnybrook and Women’s College Health Sciences CentreTorontoCanada

Personalised recommendations